フルテキストURL Vasc_Health_Risk_Manag_11_265.pdf
著者 Saito, Yukihiro| Nakamura, Kazufumi| Akagi, Satoshi| Sarashina, Toshihiro| Ejiri, Kentaro| Miura, Aya| Ogawa, Aiko| Matsubara, Hiromi| Ito, Hiroshi|
抄録  The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in randomized clinical trials. We have reported that high-dose epoprostenol therapy (>40 ng/kg/min) also results in marked hemodynamic improvement in some patients with IPAH. High-dose epoprostenol has a pro-apoptotic effect on PAH-PASMCs via the IP receptor and upregulation of Fas ligand (FasL) in vitro. However, long-term intravenous administration of epoprostenol is sometimes associated with catheter-related infections and leads to considerable inconvenience for the patient. In the future, the development of new routes of administration or the development of powerful PGI2 analogs, IP-receptor agonists, and gene and cell-based therapy enhancing PGI2 production with new routes of administration is required.
キーワード apoptosis prostacyclin pulmonary arterial hypertension
備考 学位審査副論文
発行日 2015-05-14
出版物タイトル Vascular Health and Risk Management
11巻
出版者 Dove Medical Press
開始ページ 265
終了ページ 270
ISSN 1176-6344
NCID AA12158664
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン publisher
PubMed ID 25999730
DOI 10.2147/VHRM.S50368
Web of Sience KeyUT 000210424400027
関連URL https://doi.org/10.2147/VHRM.S50368 http://ousar.lib.okayama-u.ac.jp/55246
著者 Koreishi, Mayuko| Honjo, Yasuko| Satoh, Ayano|
発行日 201-08-09
出版物タイトル Antibody Technology Journal
2011巻
1号
資料タイプ 学術雑誌論文